Delcath Systems Inc (DCTH)

[Rapture2020]

Good point. I think the discussion has tacked too negative the past couple of weeks (and with good reason, given the PPS). What impact, if any, would a massive short attack have on DCTH? If you recall, two weeks ago the shorts choppered in a bunch of posters and the PPS got bushwacked even further.

Just keeping open all reasons why the PPS has tanked lately. Could it be possible a coordinated and carefully orchestrated short attack has hijacked the narrative? The FINRA report will confirm this in another week. But until then, it merits discussion, IMO.

And no, i am NOT trying to defend the lack of transparency by DCTH. Just want to look at all possible scenarios.

Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder

NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Simon Pedder, Ph.D., a scientist and pharmaceutical executive with a greater than 30-year career in drug development, has joined the Delcath Board of Directors effective November 14, 2017.

Dr. Pedder currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. During his long career in drug development, Dr. Pedder has held several leadership positions including President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Executive Officer and Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of the Hepatitis Franchise at Hoffmann-LaRoche.

http://delcath.com/reuters-news/?id=2317872